Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?
Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...
Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Third trial failure is end-of-the-road for Sage's neurological drug
A third trial failure this year for the same experimental neurological drug has led Sage Therapeutics to discontinue ...
The Business Journals1mon
Cambridge biotech's layoffs will cut dozens of Mass. employees
In a filing Friday, it said how many of those cut are Massachusetts workers ... s Disease expected later this year. Sage and Biogen Inc. (Nasdaq: BIIB) co-developed zuranolone, which is sold ...
Hosted on MSN18d
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Based in Cambridge, MA, Biogen Inc. is one of the world’s leading biotechnology companies, which focuses on ...
European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
CNN4d
Biogen Inc.
Biogen, Inc. is a biopharmaceutical company ... and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Seeking Alpha1mon
Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter
Biogen Inc. (NASDAQ:BIIB) the central nervous system disease drug developer based in Cambridge Massachusetts, reported its Q3 earnings yesterday, Wednesday, October 30. First, let's look at some ...
Cautious Optimism for Biogen: Hold Rating Amidst European Approval Developments
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...
Seeking Alpha12d
Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales
Needham has downgraded Biogen (NASDAQ:BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s Alzheimer’s drug Leqembi. The investment bank said it doesn ...